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ABSTRACT
AMELIA GRACE HAYDEL: Investigating the Role of Rap1a in Medial Vascular
Calcification
(Under the direction of Dr. James A. Stewart, Jr.)

Cardiovascular disease is the leading cause of death in the United States with one
of the major contributors being vascular calcification, characterized by the deposition of
calcium-phosphate hydroxyapatite. Once thought to be a passive process due to aging,
medial vascular calcification is becoming better understood as a tightly regulated, cellmediated process. Vascular smooth muscle cells (VSMCs) within the medial arterial
layer respond to inflammation, oxidative stress, and changes in pyrophosphate levels,
which induce differentiation into osteoblast-like cells. Fibroblasts within the adventitial
layer (AFBs) also alter their function in response to vascular calcification signaling,
although this is largely understudied. The AGE/RAGE signaling cascade has been
implicated in medial vascular calcification. We hypothesize that the small GTPase,
Rap1a, contributes to AGE/RAGE signaling, resulting in vascular calcification. We chose
to investigate Rap1a in order to better elucidate the molecular mechanisms behind the
development of medial vascular calcification. In order to do this, in vitro studies were
conducted using VSMCs and AFBs isolated from wild-type (WT) and Rap1a knockout
(KO) mice to further investigate the possible role of Rap1a in vascular calcification. Cells
were exposed to 3 mM inorganic phosphate to simulate physiological calcification
conditions. Following seven days of treatment, a colorimetric calcification assay was
utilized to quantify intracellular calcium levels. Expression of proteins such as RAGE, αsmooth muscle actin (αSMA), osteopontin (OPN), and toll-like receptor 4 (TLR-4) were
iv

quantified via western blotting. WT VSMCs presented with equal amounts of
calcification compared to KO except with the addition of AGEs in KO cells, suggesting
that the role of Rap1a in the context of the AGE/RAGE cascade requires further
investigation. However, our data suggests that WT and KO AFB calcification is
dependent on the activation of the AGE/RAGE cascade. Therefore, we conclude that
AFBs and VSMCs differ in their mechanisms of calcification formation and that further
research is necessary to fully understand the role of AGE/RAGE and Rap1a in medial
arterial vascular calcification.
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CHAPTER I
INTRODUCTION

Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is one of the most prevalent and costly diseases
worldwide, specifically within the United States (U.S.), where it affects as many as 30
million Americans [1, 2]. These numbers will continue to rise with a growing obese and
sedentary population, necessitating a deeper understanding of the disease with prevention
and treatment being a primary focus of medical research today [3]. Diabetics exhibit an
increased risk of death due to complications of coronary and peripheral vascular disease
at a 20% to 40% increase from the non-diabetic population [4, 5]. Vascular disease is
also a leading cause of death in the United States, proving fatal for 40% to 60% of the
non-diabetic population [3]. Diabetes mellitus is present in several different forms, such
as Type 1, Type 2, and gestational diabetes. Each type of diabetes results from a different
set of risk factors and circumstances, but the increased risk for cardiovascular disease
remains high in each type.
Previously referred to as Juvenile Onset Diabetes due to its high incidence in
children, Type 1 diabetes mellitus (T1DM) can occur at any age and is characterized by a
loss of the body’s ability to secrete insulin in response to elevated blood glucose levels.
Type 1 diabetes comprises about 5% of all diabetes cases [6]. In the majority of these
cases, Type 1 diabetes is most often caused by a T-cell mediated autoimmune response
against pancreatic β-cells, which are responsible for the release of insulin [7]. Destruction
of the pancreatic β-cells results in the loss of the ability of the pancreas to release

adequate amounts of insulin to signal the uptake of blood glucose into the tissues and
cells [8]. Type 1 diabetes is commonly referred to as insulin-dependent diabetes because
of the body’s retained ability to respond to insulin [7]. Type 1 diabetes can be managed
by the administration of tightly regulated doses of insulin into the bloodstream [7].
In comparison to Type 1 diabetes, Type 2 diabetes mellitus (T2DM) is the most
common form of diabetes, most often affecting people of at least 45 years and older of
age [9]. However, with increasing rates of childhood and young adult obesity, this disease
is becoming more prevalent at earlier ages [1]. There is no single factor contributing to
the onset of Type 2 diabetes mellitus, but rather, an accumulation of contributing factors
or pathophysiologic risk factors associated with T2D. Factors most commonly associated
with the development of T2D are 1) decreased uptake of circulating glucose within the
target tissues, 2) inappropriate endogenous glucose production, and 3) elevated dietary
intake of glucose, collectively leading to elevated blood glucose levels [9, 10].
Chronically high blood glucose in combination with elevated circulating free fatty acid
and intermediary lipid metabolite molecules has been demonstrated to activate a serine
kinase cascade leading to the desensitization and disruption of insulin receptor signaling
[11]. Consequently, the loss of insulin signaling leads to decreased glucose uptake by the
cells. Therefore, Type 2 diabetes is referred to as insulin-independent diabetes, in which
simple administration of insulin will not suffice as a viable treatment [12]. In response to
the loss of blood glucose detection and decreased insulin receptor sensitivity, the body’s
metabolic activity will shift towards a fasting phenotype, resulting an inappropriate
release of glucagon from pancreatic α-cells to initiate glycolysis and further increase
blood glucose levels [10, 12].
2

Cardiovascular disease is the leading cause of death in patients diagnosed with
diabetes mellitus [2]. Persistent exposure to elevated blood glucose levels has been noted
as one of the main causal factors associated with diabetic pathologies due to obesity,
dyslipidemia, and hypertension greatly increasing the risk of diabetes-induced
cardiovascular disease, myocardial infarction, and diabetic cardiomyopathy [2, 25] While
obesity is not uncommon in Type 1 diabetic patients, the majority of Type 2 diabetic
patients are often obese [2]. Obesity makes it more difficult for patients to maintain an
active, healthy lifestyle. High levels of visceral adipose fat also have been demonstrated
to overexpress cytokines, such as tumor necrosis factor-𝛼𝛼 (TNF-𝛼𝛼), interleukin-6 (IL-6),
leptin, which collectively leads to increased inflammation, endothelial cell dysfunction,
and elevated oxidative stressors, to promote cardiomyopathies such as vascular
calcification [2].

Vascular Calcification
Cardiovascular disease (CVD) is the leading cause of death in the U.S. and is
responsible for 610,000 deaths annually [13]. Cardiovascular disease affects one out of
three adults in the U.S. with an estimated health care cost of $444 billion annually
making CVD a substantial economic burden [14]. A major determinant of cardiovascular
health of the system is the level of calcific vasculopathy present, as vascular calcification
has been demonstrated to be highly correlated to cardiovascular disease mortality, stroke,
and amputation, especially in patients with end-stage renal disease or diabetes [15, 16,
17]. Vascular calcification is characterized by the inappropriate deposition of calciumphosphate mineral, hydroxyapatite, into the extracellular matrix (ECM) [18].
3

Figure 1. Graphic illustration of the three layers of the aorta. The innermost layer or intima layer is
composed primarily of endothelial cells. The second layer or medial layer is comprised of vascular
smooth muscle cells. The outer or adventitial layer contains adventitial fibroblasts embedded within the
surrounding extracellular matrix (ECM).
Calcification of this type is typically seen within the blood vessels, the myocardium, and
cardiac valves [19].
Vascular calcification is categorized into two types as it relates 1) to the location
of the calcification and 2) to pattern of hydroxyapatite deposition [20]. The arterial vessel
is composed of three major layers: 1) the intima/lumen through which the volume of
blood flows, 2) the medial layer consisting of smooth muscle tissue, and 3) the adventitial
layer containing the network of ECM proteins and tissues for required structural support,
Figure 1 [20, 38]. Intimal calcification occurs within the intimal endothelial layer of the
artery and is associated with atherosclerosis, resulting from cellular necrosis,
inflammation, and/or improper lipid deposition [20]. Intimal calcification results in an
4

asymmetric deposition of calcification causing an uneven blockage of the lumen [16]. In
contrast, medial arterial calcification (MAC) occurs within the medial layer of the artery,
which is mainly composed of vascular smooth muscle cells (VSMCs), and unlike intimal
calcification, the pattern of hydroxyapatite deposition is generally concentric and
symmetric within the vessel layer [16]. Medial arterial calcification is attributed to
arterial stiffening and decreased vascular compliance [16, 19, 20]. Compromised vascular
compliance and increased arterial stiffness can result in an increased pulse pressure, left
ventricular dysfunction, myocardial ischemia, and heart failure [17]. This is especially
true in the context of patients with diabetes and chronic kidney disease (CKD), as medial
calcification is strongly correlated with coronary artery disease and cardiovascular
events, and high levels of medial arterial calcification in these patients increases the risk
of amputation [22]. Therefore, understanding the mechanistic pathways of medial arterial
calcification and physiological variables that may affect it is essential for the
improvement of healthcare given our aging and dysmetabolic population [16].
Once thought to be a passive calcium-phosphate precipitation process brought on
by the progression of age, medial vascular calcification is now becoming more carefully
understood as a tightly regulated cell-mediated process [17, 22]. The regulation of this
process can become especially dysfunctional in the context of chronic kidney disease,
diabetes mellitus, atherosclerosis, and aging due to dysfunction and overstimulation of
glucose-induced pathways [16, 22]. Endocrine, metabolic, mechanical, and inflammatory
cues initiate the release of paracrine signals provided by bone morphogenic protein
(BMP)-2, parathyroid hormone-related polypeptide, osteopontin (OPN), and matrix Gla
protein [16]. These skeletal pro-osteogenic mediators drive vascular pericytes, smooth
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muscle cells in the medial layer, and possibly fibroblasts in the adventitia to osteogenic
fates [23]. In response to inflammation, oxidative stress, increased transcriptional activity
of nuclear factor κ-β (NFκβ), and activation of protein kinase C-ζ (PKC-ζ), the VSMCs
within the medial arterial layer have inherent differential properties to upregulate
expression of BMPs -2 and -4, tumor necrosis factor-α (TNF-α), OPN, and type I
collagen [22, 18, 16, 17]. In addition, changes in pyrophosphate levels have also been
shown to induce VSMCs into osteogenic differentiation [22, 16]. VSMC behavior and
functionality change with this differentiation, causing the cells to enter a synthetic state
and encourage hydroxyapatite deposition in the ECM, as well as potentially affect
adventitial fibroblast behavior [22]. These behavior and functional changes in VSMCs
ultimately result in increased rigidity and stiffness within the artery [18].
The adventitial layer of arterial vessel walls is comprised of fibroblasts
encapsulated by ECM consisting of proteins such as collagens, elastin, and fibronectin
[14]. The ECM plays a notable role within the cellular microenvironment and produces
signals affecting the activation and differentiation of the surrounding fibroblasts [14].
Conversely, fibroblasts are accountable for homeostatic upkeep and pathological
alterations of the surrounding ECM [25]. The communication between fibroblasts and the
surrounding ECM is essential in the healthy maintenance of the vasculature; however, in
the context of pathologies such as T2D, biochemical and mechanical stimuli disrupt this
homeostasis, often resulting in activation of profibrotic signaling cascades and changes in
fibroblast phenotypes that lead to increased ECM deposition [25]. Fibroblasts, in their
activated, pathological state, undergo phenotypic transformation, proliferation, and
migration in the medial layer of the vessel wall [17, 26]. While this response can initially
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be beneficial to maintain vascular integrity in response to injury and stress, sustained
increases in myofibroblast population, as seen in hyperglycemic conditions, can prove to
be detrimental to vascular compliance and proper tissue remodeling [25]. Inflammation
and increased expression of OPN and BMPs within the VSMCs of the medial layer could
also contribute to the differentiation of these fibroblasts into an activated myofibroblast
phenotype, which can consequently cause increased expression of α-smooth muscle actin
(α-SMA) and secretion of cytokines such as endothelin-1 (ET-1) and TNF-α, which
further contribute to inflammation, amplified ECM hydroxyapatite deposition, and
arterial remodeling to increase vessel rigidity and decrease vascular compliance [18, 16,
17].

The AGE/RAGE Cascade
In the blood, extended exposure of aldose monosaccharides, such as glucose, to
long-lived circulating proteins and lipids has been shown to produce non-enzymatic
glycation and oxidation of these macromolecules, resulting in Schiff-base intermediates,
followed by Amadori compounds, which are then further chemically altered to produce
irreversibly crosslinked molecules; the products of these irreversible reactions are defined
as advanced glycation end products, or AGEs [27, 25]. AGEs have been observed to
naturally accumulate in the body with the progression of age; however, AGEs and their
transmembrane immunoglobulin receptors (RAGEs) are found in elevated levels in
diabetic patients and patients with chronic kidney disease due to chronically elevated
blood glucose levels [18, 28, 25]. The presence of AGEs has been implicated in the
pathogenesis of diabetic complications such as vascular fibrosis, prompting interest in
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elucidating the molecular mechanisms behind AGE/RAGE interactions and the resulting
cascade of cellular signals and effects [29, 25]. Previous investigations have led to the
conclusion that the binding of AGEs to RAGEs modulates cellular activity in various
ways, including the activation of transcription factors, such as nuclear factor κ-β (NF-κβ),
to initiate production of cytokines, like interleukin-6 (IL-6), tumor necrosis factors
(TNFs), reactive oxygen species (ROS), and increased deposition of extracellular matrix
components, such as types I and IV collagen [27, 30, 24].
The signaling pathways that result from AGEs binding to RAGEs, commonly
referred to as the AGE/RAGE cascade, have also been demonstrated to play a key role in
the development of vascular calcification, especially in the context of diabetes mellitus
and chronic kidney disease due to patients presenting with significantly higher
concentrations of circulating AGEs, Figure 2 [18, 31, 32, 25]. Similarly, proportionate
RAGE upregulation has been observed in response to increased circulating AGE levels
[18, 25] The binding of AGEs to RAGEs initiates several downstream cellular responses,
including one response thought to be involved in calcification signaling. Phosphokinase
C (PKC)-ζ, which has been demonstrated to be mediated through the p38 mitogenactivated protein kinase (MAPK) and extracellular regulated kinase ERK1/2 (p44/42
mitogen-activated protein kinase), contributes to induction of VSMC differentiation into
an osteoblast-like phenotype, most notably in hyperglycemic and calcification conditions
[18]. Other such AGE/RAGE-initiated responses implicated in the development of
calcification have been shown to occur through transforming growth factor-β (TGF-β)
and NF-κβ, both of which disrupt proper regulation and production of ECM components,
such as type I collagen in VSMCs and fibroblasts resulting to fibrosis [18, 25].
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Additionally, it has been shown using rat models that activation of the AGE/RAGE
cascade in VSMCs reduced the expression of smooth muscle-myosin heavy chain (SMMHC) and α-smooth muscle actin 22 (αSMA22), both phenotypic markers of VSMCs
[18]. This expression change is indicative of the loss of the cells’ VSMC phenotypic
markers and further suggests possible differentiation of VSMCs into osteoblast-type cells
present medial arterial vascular calcification [33,34]. Therefore, one of the goals of this
study was to determine the phenotypic changes in cells, such as VSMCs and vascular
fibroblasts, as a result of increased AGE/RAGE signaling.

Rap1a and the AGE/RAGE Signaling Pathway

Figure 2. Highlights the physiological and biochemical outcomes resulting from increased
circulating AGEs and RAGE activation due to chronic diseases, such as diabetes and
kidney disease.
9

Ras-proximate 1a, or Rap1a, is a small monomeric G-protein and a member of the
Ras superfamily of GTPases. Rap1a homologues exist within multiple signaling
pathways contained in various organ systems throughout the body and play similar roles
in these signaling pathways, usually as molecular activator/repressor switches that
connect extracellular stimuli to downstream signaling [35, 36, 38]. Consistent with the
conserved characteristics of the Ras superfamily, Rap1a contains a G-protein domain that
allows for the capability to bind guanine triphosphate (GTP) to enter into its active form
and, through subsequent hydrolysis of a phosphate, transition to its inactive, guanine
diphosphate (GDP)-bound form [35, 36, 25]. Most relevantly, Rap1a has been implicated
as a key molecule within signaling cascades involved in the maintenance and
development of vascular tissues, such as 1) Protein Kinase A (PKA)-dependent
mechanisms that utilize second-messengers, such as cyclic-adenine monophosphate
(cAMP), calcium, and diacylglycerol, and 2) activation of guanine exchange proteins
(EPACs), which undergo a conformational change upon cAMP binding, to catalyze
Rap1a nucleotide exchange and modulated binding of Rap1a to downstream
cardiovascular effector proteins [37, 38, 25].
Through their interaction with by Rap1a, the cardiovascular effector proteins have
been demonstrated to play a role in the regulation of signaling mechanisms affecting
vascular tissue cell migration, integrin-mediated cell adhesion, and cell proliferation [36,
38, 35]. Additionally, Rap1a signaling in VSMCs has been shown to activate
extracellular regulated kinase ERK1/2 (p44/42 mitogen-activated protein kinase),
especially under hyperglycemic conditions, and the stimulation of this pathway has been
implicated in the development of fibrosis within the ECM through activation of NF-κβ,
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which resulted in a diminished ability for healthy angiogenesis by endothelial cells,
leading to pathologic vascular conditions and changes in VSMC morphology [18, 36,
38].
To date, there has been a disparity in the literature about any existent relationship
between Rap1a and the AGE/RAGE cascade, despite observed increases of expression in
VSMCs under hyperglycemic conditions. Additionally, the AGE/RAGE cascade and
Rap1a have independently been shown to activate many of the same signaling pathways
such as ERK1/2, MAPK, and NF-κβ, which are each involved in the regulation of cell
growth, ECM synthesis, and fibroblast activity [25]. The independent observance of
similar cellular responses in vascular tissue to both Rap1a activation and AGE/RAGE
activity, such as increased fibrosis formation and fibroblast activation, has prompted the
investigation of how, if at all, Rap1a is involved in vascular calcification in the context of
the AGE/RAGE cascade.

11

CHAPTER II
METHODS

Animal Models
This study utilized vascular smooth muscle cells (VSMCs) and adventitial
fibroblasts (AFBs) isolated from two genotypic variants: 1) male Rap1a wildtype mice
(Rap1a +/+; Rap WT) and 2) male Rap1a knockout mice (Rap1a -/-; Rap KO). To
generate the Rap1a knockout mouse model, a targeting vector (0.95 kb; PvuII-Ndel
fragment) was used to insert a neomycin resistant gene downstream of exon 4 of the
RAP1A gene in the opposite (3’-5’) orientation. Upon the successful insertion of this
resistance gene, Rap1a mRNA expression was disrupted and the knockout genotype was
achieved [40]. Rap1a null mice have altered myeloid cell functions suggesting distinct
roles for the closely related Rap1a and 1b proteins [40]. Breeder mice were a generous
gift from Dr. Maqsood Chotani (Dr. Panjwani Center for Molecular Medicine and Drug
Research, University of Karachi, Pakistan) and Dr. Lawrence Quilliam (Indiana
University School of Medicine, USA).

Animal Care
The mice were housed under standard environmental conditions, maintained using
commercial mouse chow and tap water ad libitum. Study conditions were in accordance
with the principles of the National Institutes of Health “Guide for the Care and Use of
Laboratory Animals,” (NIH publication No. 85-12, revised 1996), and protocols were
approved by the University of Mississippi Animal Care and Use Committee (protocol
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#17-024). Adult male mice 16 weeks of age were used for this study. Carbon dioxide
inhalation, followed by cervical dislocation, were used as means of euthanasia. At this
time, the chest was opened, and the aorta was quickly excised for further cell isolation,
histological, and biochemical experiments.

Genotyping
Tail Digestion
To determine the genotype of the mice, a snip of the tail 3-5 mm long was
collected from each mouse and placed into a 1.5 mL microcentrifuge tube containing 250
μL of an alkaline lysis buffer solution, referred to as DNA extraction buffer (50 mM
NaOH diluted in nuclease-free water). The harvested tail was finely minced within the
microcentrifuge tube using a pair of sterile scissors and placed in a heat block set to 95°C
for 1 hour. Following heat digestion, the tubes were centrifuged for 5 minutes at room
temperature at 21,694 xg (Heraeus Megafuge 8R Centrifuge, Thermo Scientific). 96.4 μL
of the resulting supernatant was removed and transferred into a fresh 1.5 mL
microcentrifuge tube, along with 8 μL of 8 mM Tris-HCl buffer solution at pH 8.8.
Polymerase Chain Reaction (PCR)
A polymerase chain reaction (PCR) master mix for each sample was created,
using 15 µL of 2X Dream Taq Hot Start Mix (Thermo Fisher Scientific), 1 µL ADPR266
(5´‐ TCTATCGCCTTCTTGACGAGTTC -3´), 2 µL Rap1aKO (5´‐
CTTGCTCTCCTGTTACCTATAGGTGCC -3´), 1 µL RapExon (5´‐
CCGTAAAATCTGTTCTCTCAAGTC -3´), and 12.0 µL of nuclease-free water
(Thermo Fisher Scientific). Each PCR master mix solution component was multiplied by
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the number of DNA samples present. PCR tubes were prepared for all samples, with 28
μL of master mix and 2 μL of sample DNA added to each appropriately designated tube.
Following these additions, the tubes were placed in the thermocycler (ProFlex PCR
System, Applied Biosystems, Life Technology) and programmed according to the table
below, Table 1.

Table 1. Rap1a Genotyping
Temperature Time
Cycles
93˚C
1.5 min X 1
93˚C
30 sec
57˚C
30 sec X 40
65˚C
3 min
65˚C
3 min
X1
4˚C
Hold
Visualization of PCR Products
After the completion of the PCR procedure, a 2% agarose gel composed of 1 g
agarose (Thermo Fisher Scientific) and 50 mL of Tris-Acetate-EDTA (TAE) (Thermo
Fisher Scientific) was made by mixing the two components and microwaving them until
completely dissolved. Prior to pouring the gel into the gel electrophoresis tray, 8.5 μL of
ethidium bromide was added to the mixture. A comb was added immediately following
the addition of the gel mixture to the tray, and the gel was allotted time to polymerize.
Once the gel had polymerized and was ready for use, 3 μL of dye was combined with 15
μL of PCR product, and then 17 μL of total sample mixture was load into the wells of the
gel. In the leftmost well, a mixture of 5 μL of dye and 5 μL of DNA ladder (Thermo
Fisher Scientific) was added to run as a base pair ladder. Finally, the gel containing the
ladder and samples was run at 100 V for 1 hour in order to separate the PCR products.
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Once complete, the gel was visualized under ultraviolet light using the iBright CL1000
Imaging System (Invitrogen) to identify the genotype of the samples. A band present at
the 1358 bp mark was indicative of the wildtype (Rap1a+/+) mouse genotype, while a
band present at the 1107 bp mark was indicative of a Rap1a knockout (Rap1a-/-) mouse
genotype. When both 1358 bp and 1107 bp bands were present, it indicates a
heterozygote (Rap1a+/-) mouse.

Cell Isolation and Cell Culture
Cell Isolation
Euthanasia of the mice was achieved by carbon dioxide exposure, followed by
cervical dislocation. The mice’s body weights were then recorded. Blood glucose levels
were measured using a drop of blood obtained from a tail clip. The blood was placed on a
blood glucose test strip and analyzed by the blood glucose meter (glucometer; OneTouch
Ultra®, LifeScan, Inc., Johnson & Johnson). Prior to dissection, the mice were sterilized
by submersion in 70% ethanol. The mice were placed on a dissecting mat, where the
chest was opened, and the aorta was removed. The aortal adventitial and medial layers
were separated by manually stripping the adventitia containing the fibroblasts from the
aorta, leaving the medial layer, which contained the vascular smooth muscle cells. After
separation, the adventitial and medial layers were placed separately on ice in 1X nonsterile PBS (phosphate buffered saline; 17 mM NaCl, 0.3 mM KCl, 1.01 mM Na2HPO4,
0.18 mM KH2PO4, pH 7.4). On average, 3-4 aortas per genotype were needed for
sufficient numbers of cells in a single isolation. The remaining procedures required for
isolation were carried out in a sterile cell culture hood (1300 Series A2 Biosafety
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Cabinet). There, the adventitial layer and vascular smooth muscle layer were placed in
separate 60 mm petri dishes, where they were washed three times with 37ºC 1X sterile
PBS. Upon removal of the last PBS wash, 5 mL of a collagenase-trypsin enzymatic
solution (0.25% Trypsin, Gibco; 200 U/mL collagenase II, Worthington Biochemical)
was added to the plates containing the adventitial fibroblasts (AFBs), and 5 mL of a
collagenase-elastase-trypsin enzymatic solution (0.25% Trypsin, Gibco; 1950 U/mL
collagenase II and 11.3 U/mL elastase, Worthington Biochemical) was added to the
plates containing the vascular smooth muscle cells (VSMCs) [41, 42]. The tissueenzymatic mixtures were transferred into water-jacketed spinner flasks containing a
magnetic stir bar, where they were vigorously stirred. The water-jacketed flask allowed
37°C water to flow through the outer jacket to maintain optimal temperature conditions
for cell isolation. AFB digestion was allowed to spin for 10 minutes. The AFB enzymatic
mixture was removed via transfer pipette and strained through a 100 µm sterile
disposable cell filter (Thermo Fisher Scientific) into a 50 mL conical tube. Any tissue
remaining in the strainer was transferred back into the spinner flask, along with another 5
mL of enzymatic mixture. 5 mL of “Stop” media (high glucose media; Dulbecco’s
Modified Eagles Medium (DMEM) containing 4.5 g/L glucose, sodium pyruvate, Lglutamine, and supplemented with 14.2 mM NaHCO3, 14.9 mM HEPES, 30% heatinactivated fetal bovine serum (FBS), 2% L-glutamine, and 2X Primocin (Thermo Fisher
Scientific)) was added into the conical tubes containing the cell suspension to quench the
enzymes, and the conical tubes were then centrifuged at 170 xg (Heraeus 6 Centrifuge,
Thermo Scientific) for 10 minutes. The resulting supernatant was removed via suction
and discarded, and the cells within the pellet were resuspended in high-glucose DMEM
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media containing 15% FBS. These cells were maintained in a 37°C incubator until
completion of isolation protocol. The 50 mL conical tube used for each cell type was
deemed the cell stock suspension, and this stock tube was used to collect and store all
subsequent harvests. This protocol was repeated for only AFBs until no tissue remained
following straining. The VSMC digestion was allowed to spin for 45 minutes and then it
was removed via transfer pipette and strained through a 100 µm sterile disposable cell
filter (Thermo Fisher Scientific) into a 50 mL conical tube. Any tissue remaining in the
strainer was transferred back into the spinner flask, along with 5 mL of collagenasetrypsin enzymatic, which was spun for 30 minutes. 5 mL of “Stop” media was added into
the conical tubes containing the cell suspension, which were then centrifuged at 170 xg
(Heraeus 6 Centrifuge, Thermo Scientific) for 10 minutes. The resulting supernatant was
removed via suction and discarded, and the cells within the pellet were resuspended in
high-glucose DMEM media containing 15% FBS. These cells were maintained in a 37°C
incubator until completion of isolation protocol. Both resulting stock solutions containing
the cell suspension was centrifuged at 170 xg for 10 minutes. The cells were resuspended
in high glucose DMEM media and plated into 60 mm petri dishes demarcated by cell
type. After 24 hours, the AFBs and VSMCs were washed three times with normal
glucose DMEM (1 g glucose/L, sodium pyruvate, L-glutamine, and supplemented with
14.2 mM NaHCO3, 14.9 mM HEPES, 15% heat-inactivated fetal bovine serum (FBS),
2% L-glutamine, and 2X Primocin (Thermo Fisher Scientific)) and incubated at 37°C.
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Cell Culture
Once isolated, VSMCs and AFBs were plated on 60 mm sterile plates and placed
in normal glucose Dulbecco’s modified Eagle’s Medium (DMEM) containing 15% FBS.
These cells were maintained at 37°C in an incubator containing 95% air and 5% CO2.
Media was replaced every two days. The cells were monitored by microscopy and
passaged prior to reaching 95% confluency using a 0.25% trypsin/ 0.1%
ethylenediaminetetraacetic acid (trypsin/EDTA; Life Technology) solution. All cells for
this study were used at passage two (P2) [41, 42].
Once plates of P2 cells reached 90% confluency, the plates were separated into
the following groups: 1) Control, 2) Control + AGE (0.5 mg/ml), 3) the experimental
comparison group receiving no calcification media for 7 days, D7 NC, 4) the
experimental comparison group receiving no calcification media for 7 days + AGEs, D7
NC + AGE (0.5 mg/ml), 5) the treatment group receiving calcification media for 7 days,
D7 C, and 6) the treatment group receiving calcification media for 7 days + AGEs, D7 C
+ AGE (0.5 mg/ml). Once placed in study, the Control cells received normal glucose
DMEM 15% FBS with media changes occurring every two days throughout the 7 days of
treatment. On the seventh day of study, the Control +AGE plate received 60 µL of AGEs
(20 µL AGE/ 1mL media) for one hour. D7 NC ± AGE received normal glucose DMEM
2% FBS for the same time increments, with one plate receiving the addition of 60 µL of
AGEs (20 µL AGE/mL of media) at each media change. D7 C ± AGE received
calcification media (DMEM 2% FBS containing 3 mM inorganic phosphate) for the same
time increments, with one plate receiving the addition of 60 µl of AGEs (20 µL AGE/mL
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of media) at each media change. Table 2 is included as a reference guide for experimental
group names and description of the timeline for cell treatments.
Table 2. Experimental Group Design
Experimental Group
Experimental Description
Cells were maintained in normal glucose (DMEM 15%
FBS). Media was changed every two days throughout
Control
the study, which was stopped at day 7. Cells were
exposed to normal-glucose non-calcification media for 1
hour prior to harvest.
Cells were maintained in normal glucose (DMEM 15%
FBS). Media was changed every two days throughout
Control + AGE (0.5
the study. Cells were exposed to normal-glucose nonmg/mL)
calcification media with AGEs (0.5 mg/mL) for 1 hour
prior to harvest at day 7.
Cells were maintained in normal glucose noncalcification media (NC-DMEM 2% FBS). Media was
D7 NC
changed every two days throughout the study, which
was stopped at day 7.
Cells were maintained in normal glucose noncalcification media (NC-DMEM 2% FBS) with AGEs
D7 NC + AGE (0.5 mg/mL)
(0.5 mg/mL). Media was changed every two days
throughout the study.
Cells were maintained in normal glucose calcification
media (C-DMEM 2% FBS + 3mM inorganic
D7 C
phosphate). Media was changed every two days
throughout the study, which was stopped at day 7.
Cells were maintained in normal glucose calcification
media (C-DMEM 2% FBS + 3mM inorganic phosphate)
D7 C + AGE (0.5 mg/mL)
with AGEs (0.5 mg/mL). Media was changed every two
days throughout the study.

Calcification Assay
To measure the level of VSMCs and AFBs calcification, a calcification
quantification assay was used. Cells were cultured and treated per the previously outlined
in the cell treatment protocol on 96 well plates. Each 96 well plate contained 3 wells per
treatment group of the respective cell type in that plate. Upon completion of the seventh
day of treatment, the media was removed by vacuum aspiration, and the cells were gently

19

washed with 1X PBS. Following the removal of the PBS, the plate was transferred to a
fume hood where 250 µL of 0.6 N HCl was placed into each well containing cells. The
lid of the 96 well plate was replaced and sealed with parafilm, after which the plate was
incubated undisturbed for a complete 24 hours within the fume hood. At 24 hours of
incubation, the HCl supernatant was removed and placed into microcentrifuge tubes
appropriately labeled by group and well number. Microcentrifuge tubes containing the
supernatant were stored at -80°C until the assay was performed.
The calcium colorimetric assay buffer and chromogenic reagent were removed
from refrigeration and allowed to reach room temperature (Calcium Colorimetric Assay
MAK022, Sigma-Aldrich). During this time, the calcium standard solution was prepared
by placing 10 µL of the Calcium Standard, provided within the kit, into 990 µL of
distilled water. The standard curve was created within Row A of a new, clear 96 well
plate per the table below, Table 3.

Row A Wells
Ca2+ Amount
(µg)
µL of Ca2+
Standard
µL of 0.6 N HCl

Table 3. Calcium Standard Curve
A1
A2
A3
A4
A5
0
0.4
0.6
0.8
1.2

A6
1.6

A7
1.8

A8
2.0

0

2.0

3.0

4.0

6.0

8.0

9.0

10.0

50.0

48.0

47.0

46.0

44.0

42.0

41.0

40.0

Beginning with well B1, 50 µL of HCl supernatant per sample was placed in the
appropriate wells. Samples treated using calcification media were diluted into a 1:1 ratio
solution consisting of 25 µL of sample and 25 µL of 0.6 N HCL. The dilution of these
samples ensured a calcification reading within the readable range. Next, 90 µL of
chromogenic reagent was placed in each well containing standard solution or sample
(Sigma-Aldrich). Each well was gently mixed using the pipette. In each well containing
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either the standard curve solution or sample, 60 µL of calcium assay buffer (SigmaAldrich) was added. Once more the samples were gently mixed, and all bubbles within
the wells were eliminated to ensure accurate spectrophotometric readings. The plate was
then incubated within a dark drawer for 10 minutes at room temperature. Once 10
minutes had passed, the plate was placed in the spectrophotometer (AccuSkan GO, Fisher
Scientific) and absorbance was measured at 575 nm.
Microsoft Excel was used to determine the equation of the line formed by the
standard curve (y = mx + b). Well A1 was used to determine baseline absorbance, and the
absorbance of the individual points on the standard curve was subtracted by this value.
This adjustment allowed for quantification of the calcium present in each sample by
using the following formula: Adjusted Value = Value – (Value for 0 in the Standard
Curve). The values found by using the following formula produced a final measurement
of µg of calcium in each sample: (((Adjusted Value – b)/m)/ (µL of Sample in well)).
Any resulting negative values were interpreted as 0 µg of calcium present in that sample.

Cell and DAPI Imaging and Analysis
On the seventh day of each study, control cells were exposed for 1 hour to low
glucose 2% FBS DMEM with or without the exogenous AGEs (0.5 mg/mL). The cells,
on 60 mm plates, were imaged using a Zeiss Primovert microscope with camera (Zen
Blue 2.3 edition, Zeiss). Representative images were taken of all study groups. This
experiment also utilized cells cultured in 96 well plates to conduct DAPI imaging, which
effectively stained the nuclei of the cells present in each well and permitted quantification
of cell number to be used in normalizing calcification data to control for possible cell
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proliferation. Initially, the media was removed via vacuum suction from the wells and
washed with 1X non-sterile PBS. Following the wash, 4% paraformaldehyde was placed
on the cells for 10 minutes at 4°C. Upon the removal of the paraformaldehyde, the cells
were washed twice in 1X PBS. Following, the 1X PBS was removed from the wells and
the cells were washed with 0.1% Triton-PBS. While protecting the photosensitive
solution from light, a 1:1000 DAPI solution was prepared using 0.1% Triton-PBS. Upon
the removal of the 0.1% Triton-PBS present in the wells, 125 µL of the DAPI solution
was placed in each well. The plate was then sealed using parafilm and covered in
aluminum foil for light protection. The plate was allowed 24-hour incubation at 4°C.
After 24 hours, the plate was removed, and time was allotted for the plate to reach room
temperature in order to avoid the development of condensation on the bottom of the plate.
Once the plate reached room temperature, the DAPI solution was removed via suction,
and the cells were washed in 1X PBS. The PBS was once again removed and replaced
with fresh 1X PBS for transport and imaging. A Nikon Ti2-E inverted microscope was
used to take images of the wells at 100X total magnification for 100 ms exposure and
61% DAPI intensity. Upon acquisition of all images, DAPI-stained cells were counted
using a high content analysis software and Nikon proprietary JOBS analysis.

Alizarin Red Staining
Cells cultured in 96 well plates were utilized for Alizarin Red staining, providing
direct visualization of any developed calcification. Initially, the media was removed via
vacuum suction from the wells and washed with 1X PBS. Following the wash, 4%
paraformaldehyde was placed on the cells for 10 minutes at 4°C. Upon the removal of the
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paraformaldehyde, the cells were washed twice in 1X PBS. Following the washes, the 1X
PBS was removed from the wells and a 2% Alizarin red solution was added to the cells
and allowed to incubate for 10 minutes (2% Alizarin red stain, diH2O, pH=4.1-4.3).
Following incubation, the cells were washed three times using diH2O. The wells were
imaged using a Zeiss Primovert microscope with camera (Zen Blue 2.3 edition, Zeiss).
Representative images were taken of all study groups.

Protein Extraction
At the end of the study on Day 7, Control and Control + AGE cells were washed
with normal glucose DMEM with 2% FBS or normal glucose DMEM with AGEs, and
media was allowed to stay on the plates for 1 hour. Control and Control + AGE groups
served as an internal control for cell growth and viability. After treatments were
performed, the media was removed by vacuum suction, and the plates were washed once
with phosphate buffered saline (PBS). Once the PBS was removed, it was replaced with
100 µL of Modified Hunter’s lysis buffer (10 mM HEPES, 150 mM NaCl, 1.5 mM
MgCl2, 1 mM EDTA, 10 mM Na4P2O7, 10 mM NaF, 0.1 Na3VO4, 1% deoxycholic acid,
1% Triton X-100, and 0.1% SDS) the plates were left on ice. After 10 minutes, the plates
were manually scraped using sterile cell scrapers (Thermo Fisher Scientific), and lysates
were transferred into a 1.5 ml centrifuge tube on ice. The lysates were then sonicated at
10 A for 5 seconds, and the samples were centrifuged for 15 minutes at 21,694 xg
(Heraeus Megafuge 8R Centrifuge, Thermo Scientific) at 4°C. The supernatant was then
removed from each sample, and each lysate sample was placed into new a 1.5 ml
centrifuge tubes. The samples were stored at -80°C until a Pierce BCA Protein Assay Kit
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(Thermo Fisher Scientific) was performed according to manufacturer’s instructions to
quantify total protein concentration.

Western Blotting
Western blotting was used to determine if differences in protein expression
existed in cells between treatment groups of the VSMCs and AFBs. Using the following
antibodies osteopontin (OPN; Santa Cruz), RAGE (Santa Cruz), α-Smooth Muscle Actin
(αSMA; Sigma-Aldrich), and toll-like receptor-4 (TLR- 4; Santa Cruz) protein expression
was examined, and individual samples were normalized to β-tubulin (β-TUB, a
housekeeping protein; Santa Cruz). Western blotting was also used to examine
underlying differences in expression in RAGE and αSMA in whole aortic tissue collected
from Rap1a WT and Rap1a KO mice with samples normalized to β-TUB.

Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Using the values of protein concentration determined by the Pierce BCA Protein
Assay, 20 µg/µL of protein was electrophoresed through 12% SDS-PAGE gels (25.5%1.5 M Tris (pH 8.8)/0.4% SDS, 30%- 40% Acrylamide/Bis (37.5:1, Thermo Fisher
Scientific), 44.4%- diH2O, 1% ammonium persulfate-diH2O solution, 0.06%- TEMED).
6X SDS Protein Loading Buffer (300 mM Tris-HCl pH=6.8, 60% glycerol, 12% SDS,
0.6% bromophenol blue, 15% 2-mecaptoethanol) was added to samples, and sample plus
loading dye were heated for 5 minutes at 95°C. The total volume of the microcentrifuge
tubes was carefully loaded into the wells of the appropriate gel. 7 µL of Spectra
Multicolor Broad Range Protein Ladder (Thermo Fisher Scientific) was added to the first
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well of the gels as a molecular weight marker. The tanks containing the loaded gels were
filled with 1X Running Buffer ( 10% 10X Tris-Glycine-SDS composed of 25 mM Tris
Base, 192 mM Glycine, 0.1% SDS, pH=8.3) then transferred into a refrigerator, where
100 V were applied until the run was complete. Visualization of the blue dye at the
bottom of the gel signified a complete run.

Protein Transfer
Once the gels were run, they were removed from the tank and transferred
overnight at 4°C at 20 mA onto a methanol-activated Immobilon-P membrane (pore size:
0.45 µm) (Thermo Fisher Scientific) in 1X Transfer Buffer (10% 10X Tris-Glycine
composed of 25 mM Tris Base, 192 mM Glycine, 0.1% SDS, pH=8.3, 20% methanol,
70% diH2O) in the order as depicted in Figure 3.

Figure 3. Stacking order for transferring protein from gel to PVDF membrane in transfer cassettes.

All membranes were soaked in 100% methanol prior to addition to the cassette.
Once the membrane was allowed to soak in the cassette for 5 minutes, the gel was
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carefully removed from the glass setting, the stacker gel was manually cut off and
disposed, and the remaining gel containing the proteins was laid gently on top of the
membrane. Using a roller, all air bubbles trapped between the layers of the membrane
and the gel were eliminated. This rolling was repeated after the filter paper was placed on
top of the gel. Upon complete assembly of the cassette, it was placed into a BioRad Mini
Tank and 1X Tris-Glycine transfer buffer (25 mM Tris Base, 192 mM glycine, pH=8.3)
was added. The tank was then placed in the refrigerator at 4°C and 100 mA were applied
overnight to allow complete transfer of proteins to the PVDF membrane.

Protein Visualization
The following day, the membranes were removed from their cassettes and placed
in appropriately labeled boxes, where they were first washed with diH2O for 5 minutes.
After removing the water from the boxes, the membranes were placed on a shaker and
stained 1% Coomassie Blue staining buffer (3 g Coomassie Brilliant Blue, 45%
methanol, 10% acetic acid, 45% diH2O) for 5 minutes. Once the staining was complete,
the blots were washed in de-stain buffer solution (40% methanol, 10% acetic acid, 50%
diH2O) for 5 minutes. Each membrane was washed in de-stain solution 3 times for 5
minutes each. Following the final round of de-staining, the membranes were washed with
1X TBST (90% diH2O, 10% 10X TBS (500 mM Tris-Base, 1 M NaCl, 1 L diH2O,
pH=7.4), 0.1% Tween-20) 5 times for 5 minutes each wash. After the fifth wash, the
membranes remained in TBST and images were acquired using the Protein Gels setting
on the iBright CL1000 Imaging System (Invitrogen). Upon image acquisition, the
membranes were washed for an additional 5 times for 5 minutes each wash in 1X TBST.
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Once the washes with 1X TBST were complete the membranes were blocked
using a 5% instant nonfat dry milk (Nestle Carnation) resuspended in 1X TBST solution.
The membranes were allowed to shake with the milk block for 1 hour. After 1 hour, the
milk block was removed from the membranes. Different primary antibodies at dilutions
ranging from 1:250 to 1:500 were used for osteopontin (OPN, Santa Cruz
Biotechnology), α-Smooth Muscle Actin (αSMA, Sigma Aldrich), toll-like receptor-4
(TLR-4, Santa Cruz Biotechnology), RAGE (Santa Cruz Biotechnology), and β-Tubulin
(β-TUB, Santa Cruz Biotechnology). The appropriate primary antibody solution was then
added to the membranes, and the boxes containing the membranes in solution were
covered and sealed. The boxes were placed on a shaker inside a 4°C refrigerator to allow
overnight exposure of the membranes to the primary antibody. The following day, the
primary solution was removed from the membranes and, the membranes were washed 5
times for 5 minutes in 1X TBST. During this time, a 1% milk block solution containing
the 1:500 secondary antibody was prepared and added to the membranes, which
incubated on a shaker at room temperature for 1 hour. After 1 hour, the secondary
solutions were disposed of and the membranes were washed in 1X TBST 5 times for 5
minutes.
Following washes in TBST, the membranes were incubated for 2 minutes in ECL
Western Developing Substrate Solution (Pierce). Once incubated, the membranes were
developed using the ChemiBlots setting of the iBright CL1000 Imaging System
(Invitrogen). Exposure time was determined based upon the program’s smart-exposure
suggestion with slight adjustments being made as needed to clearly visualize the protein
bands of interest. Once the acquisition of the images was complete, the images were
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exported via USB drive for image analysis in Image J (NIH), and the membranes were
replaced in their respective boxes on the shaker for the remainder of the protocol.

PVDF Membrane Stripping
After membrane development, the ECL solution was removed and the membranes
were stripped of any antibody present using a stripping solution (62.5 mM Tris-HCl,
pH=6.7, 2% SDS, 0.7% 2-mercaptoethanol) at 50°C for 10 minutes. Following stripping,
the membranes were washed 5 times for 5 minutes each with 1X TBST. Upon the
completion of the TBST washes, the membranes were re-exposed to ECL Substrate
Solution (Pierce) and developed as previously stated, in order to ensure complete
antibody stripping had occurred. If bands were observed, the stripping procedure was
repeated until no bands appeared. Blots were then incubated in the milk block for 1 hour.
After blocking, the milk block was removed, and the protocol for adding primary
antibody was repeated using the next antibody.

Western Blot Image Analysis
To quantify the expression of each protein of interest, the NIH Image J program
was utilized to perform a densiometric analysis of the protein bands observed upon
development of the membranes. To begin, the membrane images were uploaded to the
NIH Image J program, and the colors were inverted to ensure the protein bands were
observed as dark bands on a white membranous background. Then, each membrane was
analyzed individually by using the “rectangle” tool to draw a box around the protein band
of interest. This rectangle was initially drawn to include all treatment groups to ensure
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complete inclusion of the bands of each group as the analysis was performed. A
corresponding Coomassie image of the same blot, obtained prior to antibody exposure,
was used as an overlay to ensure the correct molecular weight was used to identify the
band of interest for each gel. This step allowed for analysis of the correct protein.
Beginning with the leftmost protein band, a rectangular box containing the entire band of
protein was created for each group present on the membrane. Upon completion, curves
were generated for each band. Lines were drawn to create a uniform boundary under each
curve, and the areas under the curves were measured by quantifying the number of pixels
present under the curve. This measurement corresponded to the density of the protein
observed. The observed protein density was directly related to the level of protein
expression. This process was repeated for all membranes and all proteins of interest. All
measurements of protein expression in each sample were normalized to that samples’
measured expression of β-tubulin. β-tubulin is a structural protein with relatively
consistent expression levels with the cells studied, and was it was used as a way to ensure
equal loading of gels.

Statistical Analysis
Repeated measures analysis of variance (ANOVA) were used to compare treatment
groups using the GraphPad Prism 5 program. If a significant difference (p<0.05) was
indicated, appropriate pairwise comparison methods were used for inter-group
comparison. For all experiments, ANOVA with one grouping factor, mouse genotype or
treatment, were used. Error bars presented indicate standard error of the mean (SEM).
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CHAPTER III
RESULTS

Rap1a wildtype (WT) and Rap1a knockout (KO) mice did not have significantly
different morphological measurements
Prior to cell isolations, morphological measurements (i.e., body weights, heart
weights, and blood glucose readings) were recorded for Rap1a wildtype (WT) and Rap1a
knockout (KO) mice, Table 4. There were no significant differences reported between the
genotypes for the criteria measured. Changes in afterload as a result of loss in vascular
compliance would likely manifest in an increased cardiac workload causing the
myocardium to increase in weight. As demonstrated in Table 4, heart weights were not
significantly different indicating no hypertrophy was present.
Genotype

Heart Weight
(mg)

Body Weight (g)

Blood Glucose
(mg/dL)

Rap1a Wildtype
28.06 + 2.382
0.109 + 0.009
201.8 + 35.92
(WT) n=47
Rap1a Knockout
27.04 + 2.509
0.103 + 0.009
191.1 + 31.88
(KO) n=37
Table 4. Animal model morphological measurements are presented above. There were
no significant differences between Rap1a wildtype (WT) and Rap1a knockout (KO).
Values represent mean + standard deviation (SD)

Basal protein analysis of aortas from Rap1a WT and Rap1a KO mice demonstrated
significant differences in markers for vascular calcification
Protein analysis was performed to determine the basal levels of vascular
calcification proteins of interest, such as RAGE, α-smooth muscle actin (αSMA), and
full-length osteopontin (OPN), present in whole aorta tissue, Figure 4. We found there
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were no significant differences in RAGE protein expression between Rap1a WT and
Rap1a KO, Figure 4A. However, Rap1a WT had significantly higher αSMA and OPN
protein expression than Rap1a KO, Figure 4B and 4C, respectively. Representative
western blot images are shown in Figure 4D. Both αSMA and OPN are considered to be
downstream cellular phenotypic markers evaluated for vascular calcification progression.
Genotypic differences may preface variances in the calcification response.

Basal protein analysis of vascular smooth muscle cells (VSMCs) from Rap1a
wildtype (WT) and Rap1a knockout (KO) mice demonstrated similar trends found
in aortic tissue
Western blot analyses were performed on isolated VSMCs from Rap1a WT and
Rap1a KO, Figure 5. The values for each column were calculated by subtracting the
protein expression level of Rap1a WT protein expression level of cells. A positive
number indicates an increase in protein expression relative to Rap1a WT cells, while a
negative number indicates a decrease in protein expression. For this series of studies,
exogenous AGEs were added to elevate RAGE activation levels. In Figure 5A, RAGE
expression was not significantly altered from Rap1a WT VSMCs, and when AGEs were
added, relative RAGE protein expression levels did not change. αSMA expression levels
were then measured, and Rap1a KO values were found to be significantly reduced from
that of Rap1a WT VSMCs, Figure 5B. When RAGEs were activated by exogenous
AGEs, significant differences in in αSMA expression were observed between WT+AGE
and KO+AGE treatment groups. In Figure 5C, there were no significant changes in OPN;
however, a downward trend in OPN was observed in WT+AGE, KO, and KO+AGE
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Figure 4. Protein expression of key signaling markers of vascular calcification as
measured by western blot analysis. 4A) RAGE expression was not significantly changed
between Rap1a wildtype (WT) and Rap1a knockout (KO). 4B) α-smooth muscle actin (αSMA)
expression was significantly greater in Rap1a WT aortas. 4C) Osteopontin (OPN) expression
was also significantly increased in Rap1a WT aortas. 4D) Representative western blot images.
Blots were stripped and re-probed with antibodies Significant differences (*p<0.05) were
determined by one-way ANOVA. Graph represents mean + standard error from the mean
(SEM).
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Figure 5. Basal protein analysis of vascular smooth muscle cells (VSMCs) from Rap1a
wildtype (WT) and Rap1a knockout (KO) mice demonstrated similar trends in aortic
tissue. 5A) RAGE expression was not significantly changed between Rap1a WT and Rap1a
KO even with addition of exogenous AGEs. 5B) α-smooth muscle actin (αSMA) expression
was significantly reduced in Rap1a KO VSMCs. Addition of AGEs did not further reduce
αSMA levels in either Rap1a WT or Rap1a KO cells. 5C) Osteopontin (OPN) expression was
also decreased in Rap1a KO VSMCs but differences were not significant. 5D) Representative
western blot images. Blots were stripped and re-probed with antibodies. The values for each
column were calculated by subtracting the protein expression level of Rap1a WT VSMC from
that of the other groups of cells. A positive number indicates an increase in protein expression
relative to Rap1a WT cells, while a negative number indicates a decrease in expression relative
to Rap1a WT. Significant differences (*p<0.05) were determined by one-way ANOVA. Graph
represents mean + standard error from the mean (SEM).
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groups. Interestingly, reductions in Rap1a KO VSMC of αSMA and OPN protein
expression were consistent with lower level observed in Rap1a KO aorta tissue. Overall,
addition of exogenous AGEs to either Rap1a WT or Rap1a KO VSMCs did not alter
protein expression.

Basal protein analysis of adventitial fibroblasts (AFBs) from Rap1a WT and Rap1a
KO mice revealed different findings than observed in whole aortic tissue
Western blot analyses were performed on isolated AFBs from Rap1a WT and Rap1a KO,
Figure 6. Again, the values for each column were calculated by subtracting the protein
expression level of Rap1a WT protein expression level of cells. A positive number
indicates an increase in protein expression relative to Rap1a WT cells, while a negative
number indicates a decrease in protein expression. As with AFBs, exogenous AGEs were
added to elevate RAGE activation levels. In Figure 6A, Rap1a KO cells had significantly
higher RAGE expression than Rap1a WT AFBs, and when AGEs were added, relative
RAGE protein expression levels remained similar. αSMA expression levels were then
measured, and Rap1a KO values were found to be higher than Rap1a WT AFBs though
differences were not significant, Figure 6B. When RAGEs were activated by exogenous
AGEs, no differences were observed in αSMA expression between untreated and AGE
treated groups. In Figure 6C, there were no significant changes in OPN; however, a
decrease in OPN was observed in WT+AGE, KO, and KO+AGE groups. The reduction
in OPN expression in Rap1a KO and Rap1a KO+AGE AFBs was less than WT treatment
groups. Protein expression levels in Rap1a KO AFBs were consistently in opposition
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Figure 6. Basal protein analysis of adventitial fibroblasts (AFBs) from Rap1a wildtype
(WT) and Rap1a knockout (KO) mice opposed trends in aortic tissue. 6A) RAGE
expression was significantly increased in Rap1a KO, but it was not altered with addition of
exogenous AGEs. 6B) α-smooth muscle actin (αSMA) expression was elevated in Rap1a KO
AFBs. Addition of AGEs did not further increase αSMA levels in either Rap1a WT or Rap1a
KO cells. 6C) Osteopontin (OPN) expression was also decreased in Rap1a WT and KO AFBs
but differences were not significant. OPN levels in Rap1a KO cells were greater than Rap1a
WT. 6D) Representative western blot images. Blots were stripped and re-probed with
antibodies. The values for each column were calculated by subtracting the protein expression
level of Rap1a WT AFBs from that of the other groups of cells. A positive number indicates
an increase in protein expression relative to Rap1a WT cells, while a negative number indicates
a decrease in expression relative to Rap1a WT. Significant differences (*p<0.05) were
determined by one-way ANOVA. Graph represents mean + standard error from the mean
(SEM).
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with those observed in whole aortic tissues. Overall, addition of exogenous AGEs to
either Rap1a WT or Rap1a KO AFBs did not alter protein expression.

Vascular smooth muscle cells (VSMCs) calcification was not dependent on Rap1a
nor AGE
After 7 days of exposure to calcification media, it was found that VSMCs
isolated from Rap1a WT and KO were not significantly different, Figure 7A. Addition of
exogenous AGEs did not alter vascular calcification. Alizarin stained VSMC visually
reinforces these findings. In Figures 7B-7E, there was no significant differences in

Figure 7. Vascular smooth muscle cells (VSMCs) calcification was not dependent upon
Rap1a expression or exogenous AGEs. 7A) VMSCs isolated from Rap1a wildtype (WT) and
Rap1a knockout (KO) aortas were exposed to 7 days of calcification media. There were no
significant differences between genotypes. Exogenous AGEs did not significantly alter
calcification. Statistics were performed using a one-way ANOVA. Graph represents mean +
standard error from the mean (SEM).7B-7E) There was no significant differences in
calcification in Rap1a WT and KO in vascular smooth muscle cells, and addition of exogenous
AGEs did not change calcification levels.
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calcification in Rap1a WT and KO in vascular smooth muscle cells, and addition of
exogenous AGEs did not change calcification levels.

Adventitial fibroblasts (AFBs) calcification was dependent on AGE treatment
When AFBs were exposed to calcification media for 7 days, these cells were found to be
significantly different with the addition of exogenous AGEs, Figure 8A. Vascular
calcification was not significantly changed between genotypes. Alizarin staining visually
reinforces these findings. In Figures 8B-8E, there was a significant increase in
calcification in Rap1a WT and KO in adventitial fibroblasts with addition of exogenous
AGEs.

Figure 8. Adventitial fibroblasts (AFBs) calcification was dependent on exogenous AGE
treatment but was not altered by presence or absence of Rap1a. 8A) AFBs isolated from
Rap1a wildtype (WT) and Rap1a knockout (KO) aortas were exposed to 7 days of calcification
media. There were no significant differences between genotypes; however, when exogenous
AGEs were added, both Rap1a WT and Rap1a KO cells had significant calcification. Significant
differences (*p<0.05) were determined by one-way ANOVA. Graph represents mean + standard
error from the mean (SEM). 8B-8E)There was a significant increase in calcification in Rap1a
WT and KO in adventitial fibroblasts with addition of exogenous AGEs.
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VSMCs exposed to calcification media had an overall decrease in signaling proteins
When VMSCs isolated from Rap1a WT and Rap1a KO aortas were exposed to
calcification media for 7 days, there was an observed overall reduction in studied
signaling protein expression, Figure 9. Western blot protein analysis of RAGE
demonstrated a decrease in protein expression across genotypes. These changes were not
considered to be significant. With addition of endogenous AGEs, there appeared to be a
trend downwards for both genotypes, but this finding was not significant, Figures 9A9B. In Figures 9C-9D, there were significant differences noted occurring between Rap1a
WT and Rap1a KO genotypes for αSMA protein expression after calcification.
Additionally, Rap1a KO+AGE had a significantly greater loss of αSMA expression than
Rap1a WT+AGE VSMCs. OPN expression was decreased in both genotypes after cell
were exposed to calcification media, and the addition of exogenous AGEs did not alter
OPN levels, Figures 9E-9F. Representative blot images are displayed to the right of
graphs.

Adventitial fibroblasts (AFBs) exposed to calcification media resulted in altered
signaling proteins.
AFBs isolated from Rap1a WT and Rap1a KO aortas were exposed to
calcification media for 7 days. Western blot protein analysis was conducted for signaling
proteins, such as RAGE, αSMA, and OPN. In Figures 10A-10B, significant differences in
RAGE expression were observed between Rap1a WT and Rap1a KO genotypes;
however, when exogenous AGEs added to the calcification media, there were no
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Figure 9. Vascular smooth muscle cells (VSMCs) exposed to calcification media had an
overall decrease in signaling proteins. VMSCs isolated from Rap1a wildtype (WT) and
Rap1a knockout (KO) aortas were exposed to calcification media for 7 days, and then western
blot protein analysis was conducted. 9A-9B) There were no significant differences between
genotypes; however, when exogenous AGEs were added there was a further decrease RAGE
expression. 9C-9D) There were significant differences between genotypes for αSMA
expression with Rap1a KO having greater loss of αSMA. With addition exogenous AGEs there
was a significant loss in αSMA expression. 9E-9F) OPN expression was decreased in both
genotypes, yet AGEs did not alter OPN levels. Representative blot images are displayed to the
right of graphs. Blots were stripped and re-probed with antibodies. The values for each column
were calculated by subtracting the protein expression level of Rap1a WT VSMCs from that of
the other groups of cells. Significant differences (*p<0.05) were determined by one-way
ANOVA. Graph represents mean + standard error from the mean (SEM).
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Figure 10. Adventitial fibroblasts (AFBs) exposed to calcification media resulted in
altered signaling proteins. AFBs isolated from Rap1a wildtype (WT) and Rap1a knockout
(KO) aortas were exposed to calcification media for 7 days, and then western blot protein
analysis was conducted. 10A-10B) Significant differences in RAGE expression were found
between genotypes; however, when exogenous AGEs were no additional changes. 10C-10D)
No significant differences occurred between genotypes for αSMA expression. There was an
overall loss of αSMA expression with and without additional exogenous AGEs. 10E-10F) OPN
expression was decreased in both genotypes, yet AGEs in the Rap1a KO group caused and
increase in OPN levels. Representative blot images are displayed to the right of graphs. Blots
were stripped and re-probed with antibodies. The values for each column were calculated by
subtracting the protein expression level of Rap1a WT AFBs from that of the other groups of
cells. Significant differences (*p<0.05) were determined by one-way ANOVA. Graph
represents mean + standard error from the mean (SEM).
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additional changes in RAGE expression between untreated and treated groups.
Interestingly Rap1a KO groups had increased RAGE expression. No significant
differences occurred between genotypes for αSMA protein expression. There was
an additional loss of αSMA protein expression with additional exogenous AGEs beyond
that of the untreated AFBs from Rap1a WT and Rap1a KO, but these findings were not
significantly different, Figures 10C-10D. Lastly, OPN expression was decreased in both
calcified untreated genotypes with Rap1a KO having less of a loss in OPN protein
expression, Figures 10E-10F. Additionally, when AGEs to Rap1a WT and Rap1a KO
AFBs, there was an increase in OPN levels with Rap1a KO levels reaching levels above
controls. While these findings were not significant, they do indicate a gain in OPN
expression. Representative blot images are displayed to the right of graphs.

Toll-like receptor-4 (TLR4) protein expression in Rap1a wildtype (WT) and Rap1a
knockout (KO) aortas
While the findings from this study are novel, a clear mechanism did not emerge
with respect the role of Rap1a in RAGE-mediated signaling in vascular calcification.
From the background information TLR4 has been implicated as an alternate receptor for
RAGE ligands. To investigate the role of TLR4, Rap1a WT and Rap1a KO aortas were
analyzed for TLR4 protein expression. Our preliminary data found no significant
differences in TLR4 expression existed between the aorta tissue of Rap1a WT and Rap1a
KO genotypes, Figures 11A-11B. Representative blot images are displayed to the right of
graphs.
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Basal protein analysis of vascular smooth muscle cells (VSMCs) and adventitial
fibroblasts (AFBs) from Rap1a wildtype (WT) and Rap1a knockout (KO) mice
demonstrated significantly decreased levels of toll-like receptor-4 (TLR4)
When cellular expression of TLR4 protein levels were measured, it was found
that VSMC TLR4 expression was significantly decreased between Rap1a WT and Rap1a
WT+AGE. Therefore, adding exogenous AGEs significantly reduced TLR4 levels,
Figures 12A-12B. Rap1a KO and Rap1a KO+AGE TLR4 protein expression levels in
VSMCs were also significantly decreased compared to those of control; however no
intergroup treatment differences existed between Rap1a KO cells. In Figures 12C-12D.
AFB TLR4 expression was not significantly changed between Rap1a WT and Rap1a
WT+AGE; however, Rap1a KO and Rap1a KO+AGE TLR4 expression was significantly

Figure 11. Toll-like receptor-4 (TLR4) protein expression in Rap1a wildtype (WT) and
Rap1a knockout (KO) aortas. 11A-11B) There were no significant differences in TLR4
expression in the aorta of Rap1a WT and Rap1a KO genotypes. Representative blot images are
displayed to the right of graphs. Blots were stripped and re-probed. Statistics were performed
using a one-way ANOVA. Graph represents mean + standard error from the mean (SEM).
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reduced compared to control, Figures 12C-12D. Addition of exogenous AGEs to the noncalcification media did not alter TLR4 levels in Rap1a KO and Rap1a KO+AGE.

Toll-like receptor-4 (TLR4) protein analysis in calcified vascular smooth muscle
cells (VSMCs) and adventitial fibroblasts (AFBs) from Rap1a wildtype (WT) and
Rap1a knockout (KO) mice demonstrated decreased expression levels
TLR4 protein expression was not significantly changed from VSMC calcification
control levels, Figures 13A-13B. Uniform decreases were observed between both
genotypes as well as exogenous AGE treatment groups. In comparison, TLR4 protein
expression was elevated in Rap1a WT AFBs, and upon AGE treatment, TLR4 levels
were restored to non-calcification control levels, Figures 13C-13D. In addition, Rap1a
KO and Rap1a KO+AGE AFBs after calcification had a significant decrease in TLR4
protein expression compared to calcified Rap1a WT AFBs. Addition of exogenous AGEs
did not alter TLR4 levels in Rap1a WT and Rap1a KO groups.
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Figure 12. Basal protein analysis of vascular smooth muscle cells (VSMCs) and
adventitial fibroblasts (AFBs) from Rap1a wildtype (WT) and Rap1a knockout
(KO) mice demonstrated significantly decreased levels of toll-like receptor-4
(TLR4). 12A-12B) VSMC TLR4 expression was significantly decreased between
Rap1a WT and Rap1a+AGE. Rap1a KO and Rap1a KO+AGE levels were significantly
decreased compared to control; however no intergroup differences existed. 12C-12D)
AFB TLR4 expression was not significantly changed between Rap1a WT and Rap1a
WT+AGE. Rap1a KO and Rap1a KO+AGE TLR4 expression was significantly reduced
compared to control. Addition of exogenous AGEs did not alter TLR4 levels in Rap1a
KO and Rap1a KO+AGE. Representative western blot images. Blots were stripped and
re-probed with antibodies. The values for each column were calculated by subtracting
the protein expression level of Rap1a WT VSMC or AFBs from that of the other groups
of cells. Significant differences (*p<0.05) were determined by one-way ANOVA.
Graph represents mean + standard error from the mean (SEM).
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Figure 13. Toll-like receptor-4 (TLR4) protein analysis in calcified vascular
smooth muscle cells (VSMCs) and adventitial fibroblasts (AFBs) from Rap1a
wildtype (WT) and Rap1a knockout (KO) mice demonstrated decreased
expression levels. 13A-13B) VSMC TLR4 expression was not significantly decreased
from control levels after calcification. Uniform decreases were observed between
genotypes and treatment groups. 13C-13D) AFB TLR4 expression was significantly
decreased between Rap1a WT and Rap1a KO cells after calcification. Addition of
exogenous AGEs did not alter TLR4 levels in Rap1a WT and Rap1a KO groups.
Representative western blot images are displayed to the right of graphs. Blots were
stripped and re-probed. The values for each column were calculated by subtracting the
protein expression level of Rap1a WT VSMC or AFBs from that of the other groups of
cells. Significant differences (*p<0.05) were determined by one-way ANOVA. Graph
represents mean + standard error from the mean (SEM).
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CHAPTER IV
DISCUSSION

The specific aim of this study was to elucidate the relationship of Rap1a in medial
arterial calcification in the context of the AGE/RAGE cascade. Although both the
AGE/RAGE cascade and Rap1a have been independently linked to activation of
signaling pathways related to the development of vascular calcification, cell growth,
ECM synthesis, and fibroblast activity, the relationship between the two signaling
cascades, as well as Rap1a’s specific role in medial arterial calcification, is widely
understudied [38]. Additionally, this project was designed to study the role of Rap1a and
the AGE/RAGE cascade in the calcification of vascular smooth muscle cells and
adventitial fibroblasts. Genotypically different adult male mice either expressing Rap1a
(Rap1a WT) or not expressing Rap1a (Rap1a KO) genes were used, and their aortas were
harvested to isolate aorta vascular smooth muscle cells and adventitial fibroblasts. In
vitro cell culture calcification conditions were applied to the isolated cells to elucidate the
role of Rap1a and AGE/RAGE signaling in the development vascular calcification.
Although our data did not present a clear role for Rap1a in medial arterial calcification,
our study was able to successfully show that vascular smooth muscle cells and adventitial
fibroblasts utilize distinctly different molecular mechanisms in the development of
calcification. Most importantly, our data clearly indicates that calcification development
within adventitial fibroblasts is AGE/RAGE dependent, and it is not affected by the
presence of Rap1a.

46

Differential Expression of Signaling Molecules in Rap1a WT and Rap1a KO Aortas
and Isolated Aortic VSMCs and AFBs
Prior literature has demonstrated that Rap1a is a molecular activator/repressor
switch connecting extracellular stimuli to intracellular responses within multiple
signaling pathways throughout the body [33,34,38]. Most notably, Rap1a has been shown
to be involved in the maintenance of vascular tissues through activation of multiple
pathways affecting cell migration, cell adhesion, and fibrosis development [10, 34, 36,
37, 38]. Therefore, we hypothesized that expression of the gene for Rap1a would play an
observable role in the transduction of signals responsible for the development of
calcification in the cells studied. Initial aorta protein expression studies demonstrated
there was a differential expression of key signaling molecules in the AGE/RAGE cascade
and vascular calcification. While RAGE expression was not significantly changed
between Rap1a WT and Rap1a KO, there was a significant decrease in smooth muscle
vascular proteins and myofibroblast markers, like αSMA, and significantly reduced proosteogenic markers, such as OPN. Aortic protein analysis accounted for multiple cell
types with the tissue. Further studies were conducted to determine changes in signaling
molecules in isolated cells from the different layers of the aorta.
Basal protein analysis of VSMCs from Rap1a WT and Rap1a KO mice showed
similar trends as those observed in aortic tissue. RAGE expression was not significantly
changed between Rap1a WT and Rap1a KO even with addition of exogenous AGEs to
activate RAGE signaling. αSMA expression was significantly reduced in Rap1a KO
VSMCs, and the addition of AGEs did not further alter αSMA levels in either Rap1a WT
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or Rap1a KO cells. Lastly, OPN expression was also decreased in Rap1a KO VSMCs,
however these differences were not significant. In contrast, basal protein analysis of
AFBs from Rap1a WT and Rap1a KO mice opposed trends in aortic tissue. RAGE
expression was significantly increased in Rap1a KO, but RAGE levels were not altered
with addition of exogenous AGEs. αSMA expression was elevated in Rap1a KO AFBs,
and AGEs did not further increase αSMA levels in either Rap1a WT or Rap1a KO cells.
OPN expression was also decreased in Rap1a WT and KO AFBs but differences were not
significant. OPN levels in Rap1a KO cells were greater than Rap1a WT. With these
noticeable differences in Rap1a WT and Rap1a KO aortic VSMCs and AFBs, changes in
calcification would be predicted to occur.

Calcification Differences in Isolated Aortic VSMCs and AFBs from Rap1a WT and
Rap1a KO mice
To test this hypothesis, we cultured vascular smooth muscle cells and adventitial
fibroblasts that were genotypically different in media containing 3 mM inorganic
phosphate for 7 days to induce calcification. We found that VMSCs isolated from Rap1a
WT and Rap1a KO aortas exposed to 7 days of calcification media had no significant
differences between genotypes. Additionally, exogenous AGEs did not significantly alter
calcification. Therefore, VSMC calcification was not dependent upon Rap1a expression
or stimulation of the RAGE signaling cascade. In contrast, we found that AFB
calcification was dependent on exogenous AGE treatment but was not altered by
presence or absence of Rap1a. AFBs isolated from Rap1a WT and Rap1a KO aortas
exposed to 7 days of calcification media displayed no significant differences between
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genotypes; however, when exogenous AGEs were added to activated the RAGE signaling
cascade, both Rap1a WT and Rap1a KO AFBs displayed significant calcification. These
findings were in contrast to our initial hypothesis. With the calcification data
demonstrating the development of cell-mediated differences rather than changes based
upon genotype differences, further studies were need to determine the mechanisms
utilized in calcification of these two cell types. We additionally looked at differences in
expression of key signaling proteins downstream from the Rap1a or AGE/RAGE
signaling cascades to determine if Rap1a may have been playing a more passive role in
calcification.

Molecular Signaling Differences in VSMCs and AFBs Exposed to Calcification
Conditions
As previously demonstrated, under calcification conditions, RAGE expression
levels were unchanged between Rap1a WT and Rap1a KO VSMCs, and there were no
significant differences in RAGE expression between genotypes when exogenous AGEs
were added despite the presence of a slight decrease in RAGE levels. There were
significant differences between genotypes for αSMA expression with Rap1a KO having
greater loss of αSMA levels with and without the addition exogenous AGEs. OPN
expression was decreased in both genotypes, yet AGEs did not alter OPN levels. Our data
describing changes in RAGE expression in VSMCs presented no change between the two
genotypes. With increased RAGE expression and related AGE/RAGE signaling
activation being directly implicated in calcification, our data further confirms our
hypothesis that Rap1a does not play a role in the direct signaling of calcification in
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VSMCs [18, 25]. More investigation into the claim that Rap1a may indirectly play a role
in helping to preserve the integrity of VSMCs through protein expression modulation is
necessary. In addition, we demonstrated knocking Rap1a out in vascular smooth muscle
cells caused a significant decrease in expression of α-SMA; not surprisingly, this data
remains consistent with the significant difference observed in α-SMA expression in the
whole tissue data and VSMC data taken at baseline. This finding is also consistent with
the phenotypic response observed when VSMCs are driven into osteogenic fates as a
result of changes in pyrophosphate levels, inflammation, and oxidative stress and
suggests that the VSMCs were transitioning into an osteoblast-like phenotype [22, 18, 16,
24]. Indication of a phenotypic shift in VSMCs to a pathogenic state in the absence of
Rap1a leads us to consider Rap1a as a modulator of, rather than a molecular activator
contributing to, VSMC calcification signaling. Ultimately, our western blot data
presented no observed increase in expression of the skeletal pro-osteogenic mediator
OPN in the Rap1a knockout VSMCs as one would expect [16]. However, while there was
some full-length OPN expression observed, most of the OPN shown through western blot
development was cleaved, indicating that the use of a different commercial antibody to
look at OPN expression may be warranted in further research.
In looking at how the absence of Rap1a affected key signaling protein expression
in adventitial fibroblasts, we further observed a significant increase in RAGE expression
in the Rap1a knockout AFBs consistent with the difference observed at baseline. When
AFBs isolated from Rap1a WT and Rap1a KO aortas were exposed to calcification media
for 7 days, western blot protein showed significant differences in RAGE expression
between genotypes; however, when exogenous AGEs were no additional changes
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occurred. This finding may corroborate the hypothesis that Rap1a may play a role in
preserving the integrity of these cardiovascular cells through signaling modulation, as it
has been shown that increased AGE/RAGE activity, consistent with increased RAGE
expression, leads to pathogenic morphological changes to cellular activity resulting in
increased fibrosis, inflammation, and calcification [18, 28, 25]. Contrary to the increased
α-SMA expression observed in the AFBs at baseline, both genotypes experienced marked
decreases in α-SMA expression after treatment with the Rap1a knockout cells
experiencing the greatest drop from baseline expression. We found that no significant
differences occurred between genotypes for αSMA expression, but there was an overall
loss of αSMA expression with and without additional exogenous AGEs. This is a
surprising find, as we expected to see an increase in expression of α-SMA upon the
removal of Rap1a due to AFB phenotypic transition into an activated myofibroblast
phenotype in response to increased profibrotic signaling [17, 26, 25]. We also found that
OPN expression was decreased in both genotypes, yet AGEs in the Rap1a KO group
caused and increase in OPN levels. In combination with the trend of increased OPN
expression in the knockout AFBs compared to the Rap1a wildtype cells, this finding
leads us to question whether the fibroblasts are transitioning into an osteoblast-like cell
type; however, further research into this hypothesis is necessary. Ultimately, this data
corroborates the hypothesis that Rap1a plays an indirect but important role in
calcification through modulation of signaling for protein expression in AFB calcification.

The AGE/RAGE Cascade and Vascular Calcification
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In the aforementioned studies, we looked at the role of Rap1a in the context of the
AGE/RAGE signaling cascade by activating RAGE with the addition of exogenous
AGEs. Based on the current literature, both Rap1a and AGE/RAGE are implicated in
participating in related cellular processes within the cardiovascular system; therefore, we
hypothesized that Rap1a may play a role in the transduction of signals in the AGE/RAGE
cascade [18, 27, 29, 25]. Specifically, we expected to see an increase in calcification in
the presence of Rap1a with the stimulation of the AGE/RAGE cascade due to Rap1a
possibly connecting extracellular RAGE activation to intracellular responses in the form
of fibrosis development and cellular phenotypic changes [18, 25].
Independent of the expression of Rap1a, we observed no change in calcification
development with the stimulation of the AGE/RAGE cascade via addition of exogenous
AGEs in the vascular smooth muscle cells. Surprisingly, we saw a significant increase in
the formation of calcification in both genotypes of the adventitial fibroblasts with the
addition of exogenous AGEs, demonstrating that the adventitial fibroblasts operate using
an AGE/RAGE dependent calcification mechanism. Additionally, adding exogenous
AGEs helped elucidate the role of Rap1a in the modulation of molecular signaling shown
through changes in signaling protein expression. We observed that adding AGEs in AFBs
lacking Rap1a caused a non-statistically significant increase in OPN expression
compared to their counterparts lacking the stimulation of the AGE/RAGE cascade,
showing that removing Rap1a results in disinhibition of the increasingly stimulated
AGE/RAGE cascade. This finding supports the hypotheses that Rap1a acts a modulator
of the consequences of the AGE/RAGE cascade, and that the fibroblasts may be
differentiating into an osteoblast-like cell type in their calcification response.
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Additionally, both Rap1a wildtype and knockout VSMCs and AFBs exhibited further
decreases in α-SMA expression from their counterparts who did not receive AGEs,
although these decreases were not statistically significant. While the changes in signaling
protein expression observed with the addition of AGEs were not necessarily statistically
significant, the trends could possibly support our idea that Rap1a is modulating signaling
activity to negatively impact vascular calcification through AGE-mediated mechanisms.
AGE has been demonstrated to bind to a number of different receptors besides RAGE.
Therefore, we chose to investigate any changes in TLR4 expression in the context of
Rap1a and the AGE/RAGE cascade due to background information implicating TLR4.
TLR4 has been demonstrated to act as an alternate receptor for RAGE ligands,
such as AGEs. At baseline, there were no significant differences in TLR4 expression in
the aortas of Rap1a WT and Rap1a KO genotypes. Further investigation showed VSMC
TLR4 expression was significantly decreased between Rap1a WT and Rap1a WT+AGE.
Rap1a KO and Rap1a KO+AGE levels also had significantly decreased TLR4
expression. We also found that AFB TLR4 expression was not significantly changed
between Rap1a WT and Rap1a WT+AGE; however, upon western blot analysis in Rap1a
KO cells, Rap1a KO and Rap1a KO+AGE groups had a significant reduction in TLR4
expression. The addition of exogenous AGEs did not significantly alter TLR4 levels
between Rap1a KO and Rap1a KO+AGE groups. In these studies, both VSMCs and
AFBs Rap1a WT and Rap1a KO cells with AGE addition, KO cells experienced
significantly decreased TLR4 expression compared to their WT counterparts as well as
those cells not receiving exogenous AGEs. When these cells were exposed to
calcification media for 7 days, VSMC TLR4 expression was not significantly decreased
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from control levels, and AGE treatment did not alter TLR4 protein expression levels.
AFB TLR4 expression was significantly decreased between Rap1a WT and Rap1a KO
cells after calcification, and the addition of exogenous AGEs did not alter TLR4 levels in
Rap1a WT and Rap1a KO groups. These responses suggest that the TLR4 and RAGE
pathways may counterbalance each other in these cells. We hypothesize that Rap1a acts
as a modulator of the RAGE cascade allowing for increased expression and activity of
TLR4 in the cells. In contrast, in the absence of Rap1a and overactivation of the RAGE
cascade by the addition of exogenous AGEs, we observed a marked decrease in TLR4
expression, even at baseline after only an hour of exposure to AGEs. Further studies are
necessary; however, if valid, this supports the claim of this study that Rap1a is a
modulator of cellular response to consequences of calcification and the activity of the
AGE-mediated cascades.

Summary and Conclusion
Although the findings of this study were novel, we were not able to define a clear
mechanism by which Rap1a operates in the development of medial arterial vascular
calcification. Our data suggests that Rap1a is not directly involved in the mechanisms
that vascular smooth muscle cells and adventitial fibroblasts utilize in the development of
calcification. However, our findings clearly demonstrated that the two cell types studied
utilize different mechanisms in the development of calcification. Specifically, the data
showed that calcification of AFBs is dependent on the activation of the AGE/RAGE
cascade and possibly Rap1a plays a minor to inconsequential role in calcification. In
contrast, VSMCs showed no changes in calcification development in response to the
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activation of AGE/RAGE or the removal of Rap1a, leaving the mechanisms of
calcification in VSMCs a topic for further study. While our findings did not suggest a
direct role of Rap1a in the calcification of these cells, we were able to observe how
Rap1a may be indirectly involved in cellular responses to calcification conditions through
looking at changes in signaling protein expression. In the VSMCs, the removal of Rap1a,
especially when combined with the activation of the AGE/RAGE cascade, resulted in
significantly decreased expression of α-SMA. In the AFBs, knocking out Rap1a resulted
in significantly increased RAGE expression. Both removing Rap1a and stimulating the
AGE/RAGE cascade caused a trending increase in expression of OPN in the AFBs,
especially when combined. This data leads us to conclude that Rap1a plays an indirect
but important role in calcification through modulation of signaling for protein expression,
ultimately mediating cellular response to consequences of calcification conditions and the
activity of the AGE/RAGE cascade.

Limitations and Future Directions
This study independently examined the mechanisms of calcification of adventitial
fibroblasts and vascular smooth muscle cells; however, cellularly independent studies
may have hindered our lab from uncovering the true calcification mechanisms as they
occur in vivo. Due to the highly communicative nature of fibroblasts, the loss of cellular
communication between cells could have resulted our inability to determine the
calcification mechanisms of VSMCs as they may be dependent on communication with
fibroblasts. Fibroblasts, in pathologic conditions, have been shown to undergo phenotypic
transformation, proliferation, and migration into the medial layer of the vessel wall [17,
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26]. Therefore, future research may wish to pursue this idea by culturing whole arterial
tissue ex vivo in order to examine this mechanism. Additionally, the investigation of
protein expression in this study was limited by the availability of antibodies that were
successful in our study. Moving forward, using a different commercial antibody that is
successful in the detection of full-length OPN, rather than the OPN protein fragments,
may increase our understanding of the vascular calcification mechanisms. Also, moving
forward with the findings of this study, we would like to examine more closely how
Rap1a may be altering expression of other noteworthy signaling proteins, such as p38
mitogen-activated protein kinase (MAPK) and extracellular regulated kinase ERK1/2
(p44/42 mitogen-activated protein kinase), which have both been implicated in
differentiation of VSMCs into osteoblast-type cells present medial arterial vascular
calcification to better understand the mechanisms for calcification development in
VSMCs [33, 34]. Furthermore, we would like to further investigate the possible
differentiation of both VSMCs and AFBs into osteoblast-like cells by examining other
bone marker proteins such as osteocalcin (OCN). Finally, it may be worthwhile to look at
mRNA expression for these proteins as well, rather than solely utilizing western blot
analysis, to see if there are any discrepancies in the two modes of analysis.
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